The latest trading day saw Gilead Sciences (GILD) settling at $106.67, representing a -0.38% change from its previous close.

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.87, denoting a -1.53% change from the preceding trading day.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...

To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.

Hepatitis C Diagnosis and Treatment The hepatitis c diagnosis and treatment market size are predicted to develop because of the factors suc ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

The landscape for so-called PrEP drugs is evolving rapidly: While Gilead expects FDA approval in June of lenacapvir to be injected twice-a-year to halt the AIDS virus, it is making plans for the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV ...

Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence ...

The company is best known for its HIV and hepatitis C therapies, including Biktarvy ... Looking ahead, for 2025, Gilead projects product sales between $28.2 billion and $28.6 billion, and expects ...